ethyl- p- ((E)- 2- (5,6,7,8- tetrahydro- 5,5,8,8- tetramethyl- 2- naphthyl)- 1- propenyl)benzoic acid

used in psoriasis therapy; structure given in first source

Also Known As:

Ro 13-6298; arotinoid Ro 136298; arotinoid ethyl ester; ethyl-p-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoate

Networked: 15 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Skin Diseases (Skin Disease) 01/01/1987 - "Arotinoid ethyl ester (Ro 13-6298): a long term pilot study in various dermatoses." 01/01/1985 - "In preliminary clinical trials, arotinoid ethyl ester [(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1- propenyl]benzoic acid ethyl ester; TTNPB ethyl ester] was found to be highly effective in the treatment of severe and etretinate-resistant dermatoses. "
2.	Mycosis Fungoides 01/01/1987 - "The present study describes a case of mycosis fungoides, limited to the skin, which was successfully controlled with the arotinoid Ro 13-6298. " 11/18/1983 - "Five patients with T-cell lymphoma of the skin (mycosis fungoides; Sézary syndrome) were given parenterally arotinoid ethyl ester (Ro 13-6298) at a daily dose of 0.5-4.0 micrograms/kg body weight, to a total dose of 20 mg over maximally 31 weeks. "
3.	Acne Vulgaris 01/01/1986 - "Four patients suffering from severe nodulocystic acne were treated with arotinoid Ro 13-6298 for 2-5 months without improvement. " 01/01/1986 - "This study suggests that neither etretin nor arotinoid Ro 13-6298 will replace isotretinoin in the treatment of severe nodulocystic acne." 01/01/1986 - "Arotinoid Ro 13-6298 and etretin: two new retinoids inferior to isotretinoin in sebum suppression and acne treatment."
4.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/1983 - "Therapeutic effect of arotinoid Ro 13-6298 in psoriasis." 07/01/1988 - "This article discusses important aspects of the use of etretinate, isotretinoin, acitretin, and arotinoid ethyl ester in the treatment of severe forms of psoriasis." 09/01/1983 - "Two patients with severe generalized psoriasis and psoriatic arthritis whose conditions had failed to respond to oral therapy with traditional remedies, including etretinate (both patients) and its combination with psoralen and UV-A (PUVA) (one patient) were successfully treated with minimal oral dosages of the arotinoid RO 13-6298 (0.05 to 0.1 mg/day). "
5.	Hyperplasia 05/19/1986 - "Epidermal transglutaminase activity and stratum corneum turnover were examined in all-trans-retinoic acid and arotinoid ethyl ester treated hairless mice, to evaluate the possible contribution of decreased epidermal cell loss to the induction of hyperplasia by retinoids. " 09/01/1989 - "We investigated the effects of the retinoids, all-trans retinoic acid (t-RA), 13-cis retinoic acid, etretinate, and arotinoid ethyl ester, on 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced DNA synthesis, and epidermal hyperplasia in hairless mouse skin. "

Related Drugs and Biologics

1.	Etretinate
2.	4- (2- (5,6,7,8- tetrahydro- 5,5,8,8- tetramethyl- 2- naphthalenyl)- 1- propenyl)benzoic acid
3.	Benzoic Acid (Potassium Benzoate)
4.	Esters
5.	Isotretinoin (Accutane)
6.	Acitretin
7.	Retinoids
8.	ethyl- p- ((E)- 2- (5,6,7,8- tetrahydro- 5,5,8,8- tetramethyl- 2- naphthyl)- 1- propenyl)benzoic acid
9.	Tretinoin (Retinoic Acid)
10.	Therapeutic Uses

Related Therapies and Procedures

1.	Therapeutics